Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Recent Data in Relapsed/Refractory CLL/SLL

December 27th 2023

An expert on hematologic malignancies discusses recent data from ASH 2023 in relapsed/refractory CLL/SLL, highlighting the ALPINE study investigating zanubrutinib versus ibrutinib.

What Fellows Need to Know: Key Takeaways From ESMO 2023

December 26th 2023

The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible.

Future Perspectives in Large B-Cell Lymphoma

December 26th 2023

Fred Locke, MD shares his perspective on the future treatment paradigm in large B-cell lymphoma, emphasizing CAR-T cells, allogeneic strategies, bispecifics, toxicity management, and treatment sequencing.

Emerging Bispecifics in the Treatment Paradigm for R/R LBCL

December 26th 2023

Expert discusses the emergence of recently approved bispecific antibodies in R/R LBCL, emphasizing the importance of toxicity management for adverse events such as cytokine release syndrome (CRS).

Monitoring Patients Being Treated for AML

December 22nd 2023

Insight into monitoring patients who are being treated for AML, what constitutes complete remission, and how and why it’s important to test for minimal residual disease to determine a patient’s risk for relapse.

First-Line Treatment Options for AML

December 22nd 2023

Catherine E. Lai, MD, MPH, discusses the current standard of care in the first-line treatment of patients with AML and which factors guide therapy selection.

The Role of Molecular Testing in the Diagnosis of AML

December 22nd 2023

Expert perspectives on the role of biomarker testing in the diagnosis and management of acute myeloid leukemia.

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

December 22nd 2023

Elizabeth Budde, MD, PhD, presents data from the 3-year follow-up from a pivotal phase II study investigating mosunetuzumab monotherapy in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies.

Faculty Introductions

December 22nd 2023

Panelist introductions by Gregory Roloff, MD from the University of Chicago Comprehensive Cancer Center, Chicago, Illinois; Jae Park, MD, Memorial Sloan Kettering Cancer Center, New York, New York; and Bijal Shah, MD, from the Moffitt Cancer Center, Tampa, Florida.

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients With Relapsed/Refractory LBCL: Primary Analysis of a Phase Ib/II Study

December 22nd 2023

Elizabeth Budde, MD, PhD, presents data from on mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma.

Zanubrutinib Plus Sonrotoclax in Patients With Treatment-Naïve CLL/SLL

December 21st 2023

Nicole Lamanna, MD, discusses the results from the ongoing BGB-11417-101 study investigating combination zanubrutinib plus sonrotoclax in patients with treatment-naïve CLL/SLL.

CLL: Updated Data in the Frontline Setting Presented at ASH 2023

December 21st 2023

A hematologist/oncologist previews updated data presented at ASH 2023 for patients with B-cell malignancies.

Targeted Therapy and Role of Biomarkers in B-Cell Malignancies

December 21st 2023

Nicole Lamanna, MD, gives an overview of targeted therapies and the role of prognostic markers in the treatment of B-cell malignancies.

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

December 20th 2023

Claire Roddie, MD, PhD, presents data from the pooled analysis of the ongoing FELIX phase Ib/II study investigating obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.

Efficacy and Safety of Luspatercept versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naïve Patients with Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Full Analysis of the COMMANDS Trial

December 19th 2023

Guillermo Garcia-Manero, MD, presents data from the COMMANDS trial investigating luspatercept in erythropoiesis-stimulating agent-naive patients with transfusion-dependent lower-risk myelodysplastic syndromes.

Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma

December 19th 2023

Key opinion leaders on diffuse large B-cell lymphoma management provide a review first-line treatment options.

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

December 19th 2023

Raajit K. Rampal, MD, PhD, presents data from the MANIFEST-2 study investigating pelabresib in combination with ruxolitinib in Janus kinase inhibitor treatment–naïve patients with myelofibrosis.

Diagnosing Polycythemia Vera (PV)

December 19th 2023

Experts explain how polycythemia vera is diagnosed and the typical symptoms a patient may present with.

COMING SOON: Insights: Early Detection and Treatment of Veno-Occlusive Disease

December 19th 2023

Sergio Giralt, MD, provides a look at an upcoming OncLive Insights program in which he will offer insights on the evolving treatment landscape for patients with veno-occlusive disease.

Observations in Progression Post-CAR T for Lymphoma

December 19th 2023

A comprehensive overview of clinical and patient factors that impact disease progression beyond CAR T-cell therapy in lymphoma.